Best Nootropics for Alzheimer’s

2 53862

Alzheimer's and nootropicsAlzheimer’s disease:

Life expectancy in most Western countries is rising, which means that people now live longer than ever before. It is likely that this pattern will slowly continue. This is great news for all of us, but there is the other side of the coin. With longer life expectancy comes aging, which is the biggest risk factor for various neurodegenerative disorders, such as Alzheimer’s disease (AD).

That is why majority patients with AD are 65 and older. AD accounts for a large proportion (between 60-80%) of dementia cases and over 47.5 million people worldwide suffer from AD or other types of dementia. AD is therefore a major public health affecting patients and their families.

What causes Alzheimer’s disease?

AD is a very complex, progressive motor neuron disease which is linked to different causes. Alzheimer’s risk factors are physical inactivity, smoking, diabetes, obesity, hypertension and depression. Its complexity is not fully understood and despite some great recent advancements in medicine, there is still no single cure for this debilitating disease.

A lot of money is being invested in research of AD so that root causes can be identified thereby helping to find a cure for it. Some great recent studies demonstrate that scientists are constantly searching for medication and treatments against AD.

For example, one of the latest science discoveries in this field shows that high doses of resveratrol (a naturally occurring compound in various types of food) is an effective cure to prevent further deterioration in patients with AD when compared to placebo. Although, it was the largest and longest clinical trial of resveratrol in humans, more research is needed to determine its effectiveness in treating mild to moderate AD.

Another recent study from Canada has linked fatty acid deposits in the brain with an increased risk of AD. Researchers discovered that accumulation of fat droplets produced by the brain that occurs with normal aging process may predispose individuals to AD. These studies demonstrate the complex nature of AD and difficulties studying it.

A number of theories have been proposed to explain the onset of AD. One of the theories suggests that AD is caused by the accumulation of beta-amyloid (a protein fragment) in the brain. Accumulation of beta-amyloid is known as amyloid plague, which subsequently damages neurons and leads to a gradual death of brain cells.

Damage to neurons, specifically synapses, prevents effective communication and signal transmission between neurons in the brain. Lack of effective communication between nerve cells results in a loss of brain function.

“Healthy neurons are involved in numerous functions, like storing memories, processing thoughts and emotions, planning and initiating body movements.”

Therefore, it is crucial to maintain neurons fully functioning and in good health for as long as possible. Otherwise, there may be negative cognitive and behavioural consequences.

Pharmacological strategies studied in the treatment and management of AD include psychostimulants, neuropeptides, anti-inflammatory agent, cholinergic enhancers and nootropics. Most of these strategies help with the symptoms of AD.

AD has been associated with the abnormalities of several neurotransmitter systems in the brain. It is well-known that patients with AD have seriously low levels of acetylcholine neurotransmitter. Furthermore, degeneration of the cholinergic system underlies memory loss associated with AD. Therefore, a number of pharmacological treatments have focussed on delaying and minimising cholinergic neurodegeneration in order to maintain cognitive function. This is sometimes called “cholinergic hypothesis” of cognitive dysfunction.

Best nootropics for Alzheimer’s:

“Nootropics is a safe class of compounds specifically designed to improve memory and learning capacity.”

Originally, the term nootropic derived from two Greek words: “noos”, meaning “mind”, and “tropein”, meaning “towards”. Nootropics are also known as “smart pills” and cognitive enhancing agents that are designed to prevent cognitive decline and facilitate cognitive functions. Various nootropics have been studied in the treatment of cognitive diseases, including Alzheimer’s disease.

For example, Piracetam has been originally developed to treat chronic neurodegenerative disorders, such as Alzheimer’s disease. Similarly, Noopept an neuroprotective dipeptide has been shown to have significant normalising effects in cognitive deficiency in rats. Nootropics exert their effects via different systems in the body and cholinergic system is one of them.

Cholinergic system and its main neurotransmitter – acetylcholine underpin a number of very important cognitive functions, such as learning, memory, focus, decision making and sensory perception. The human body cannot produce enough acetylcholine without the sufficient levels of choline.

Although, this nutrient is naturally found in our diet, the consumed levels are very low. This places a lot of people at risk of choline deficiency. Therefore, high quality choline supplements, such as Alpha GPC, CDP-Choline (aka Citicoline), Centrophenoxine and Choline Bitartrate can prevent the choline deficiency.

For full benefits of acetylcholine precursors, they should be taken in combination with agonists. This induces a synergistic effect. Nootropics of the racetam family are known to be acetylcholine agonists. They stimulate the synapses, but do not produce extra acetylcholine. When the acetylcholine agonists are stacked with a choline source, the synergistic effects can be additive and very powerful.

Thus, Coluracetam, Phenylpiracetam and Pramiracetam play an important role in the regulation of acetylcholine levels. As one nootropic increases the number of synapses, another nootropic boosts the production of the neurotransmitter. Such combination of nootropics is beneficial for the synaptic plasticity. Similarly, acetylcholinesterase (AChe) inhibitors or anti-cholinesterase, like Huperzine A may also bring positive improvements by inhibiting the cholinesterase enzyme from breaking down acetylcholine.

buy nootropics online

 

 

A step-by-step guide to using nootropics:

Alzheimer’s patients can benefit from using nootropics. The recommended dosages of different nootropics and their combinations (i.e., nootropic stacks) are presented below.

In order to prevent choline deficiency you should take one of the choline supplements. Here are the best choline sources:

Alpha GPC – the recommended daily dosage is between 300 – 600 mg taken twice per day. You should take Alpha GPC with breakfast in the morning and then early in the afternoon preferably with a meal. View prices here

Centrophenoxine (CPX) – the recommended daily dosage is between 250 – 1000 mg taken in two equal administrations throughout the day. Take Centrophenoxine once in the morning and once in the early afternoon. View Prices here

Choline Bitartrate – the recommended daily dosage is between 500 – 1000 mg. You can take Choline Bitartrate in one dosage or split it in two equal administrations (e.g., one in the morning and one in the afternoon). View Prices here

The choline supplement should be taken with one of the racetams that are acetylcholine agonists. The best racetams for Alzheimer’s are:

Phenylpiracetam – the recommended daily dosage is between 200 – 600 mg taken in 2 equal dosages throughout the day. Phenylpiracetam should be taken with a meal. View Prices Here

Coluracetam – the recommended daily dosage is between 120 – 200 mg taken in 3 equal administrations throughout the day. Coluracetam should be taken with a meal. View Prices Here

Pramiracetam – the recommended daily dosage is between 800 – 1200 mg taken in 3 equal dosages throughout the day. Pramiracetam should be taken with a meal. View Prices Here

A good alternative to the above racetams is Huperzine A, which is an acetylcholinesterase (AChe) inhibitor. The recommended daily dosage of Huperzine A is between 50 – 200 mcg taken in 2 equal dosages throughout the day. Huperzine A should not be used on a continuous basis for longer than 2 weeks.

View Prices Here

Finally, you should add Omega-3 to your nootropics stack. You should take between 1000-3000 mg of Omega-3 per day to repair membranes. View Prices Here

Conclusion:

Needless to say that more controlled studies are needed to investigate the effects of nootropics in the treatment and prevention of AD, but the potential of nootropics is very promising. The above listed nootropics and nootropic stacks can have some great therapeutic implications in patients with AD.

 

Micheal Cavalier
I started teaching at a young age and have always had a keen interest in helping others. I have been working with college students for a number of years now. I continuously search for innovative teaching techniques to help students improve and develop their studying skills and reach goals and since my discovery of nootropics this seemed like the perfect match. I want to share the latest key information and studies on the function of nootropics, which is a very promising area that has made important contributions to understanding how the brain works and has opened up a new era of research.

SIMILAR ARTICLES

  • David

    This is an eye opener. I often struggle to wonder why nootropics have never been promoted more!

    My Grandma is unfortunately suffering from Alzheimer’s, its good to see that you are promoting nootropics. Advice is out there if you look in the right places!

  • www.allchemy.eu

    Very nice article! The only thing I noticed missing is Aniracetam.
    From NCBI:
    “One hundred and nine elderly patients suffering from mild to moderate cognitive impairment fulfilling NINCDS-ADRDA criteria for probable dementia of the Alzheimer type were treated for 6 months with a new nootropic drug, aniracetam (Ro 13-5057) in a double-blind randomized study versus placebo. The two treatment groups were comparable at baseline for demographic and behaviourial parameters and symptomatology. Patients underwent clinical, behaviourial and psychometric evaluation every other month. The aniracetam group differed significantly from the placebo group by the end of the study and also showed a statistically significant improvement versus baseline in the psychobehavioural parameters, while in the placebo group a steady deterioration was observed. Tolerability to aniracetam was excellent.”